What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms

被引:2
作者
Freeman, Jeffrey S. [1 ]
Horton, Edward S. [2 ]
机构
[1] Philadelphia Coll Osteopath Med, Div Endocrinol & Metab, Philadelphia, PA 19131 USA
[2] Joslin Diabet Ctr, Boston, MA 02215 USA
关键词
type; 2; diabetes; management; efficacy; safety; ADD-ON THERAPY; INADEQUATE GLYCEMIC CONTROL; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPAIRED GLUCOSE-TOLERANCE; PROTAMINE HAGEDORN INSULIN; INCRETIN-BASED THERAPIES; TWICE-DAILY EXENATIDE; TO-TARGET TRIAL; BASAL INSULIN; DOUBLE-BLIND;
D O I
10.1097/MJT.0b013e31826fc5e5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Insulin, the first treatment for diabetes, was discovered >90 years ago. Since then, many new types of insulin have become available, including analogs that more closely mimic the characteristics of endogenous insulin. In addition, oral antidiabetes drugs and other types of injectable therapies have been approved for the treatment of patients with type 2 diabetes. As newer treatments are approved for type 2 diabetes, the choice and-paradoxically-the complexity of treatment increases. The potential benefits of all treatment options must be carefully balanced against potential adverse events to truly analyze the overall efficacy, safety, tolerability, and potential long-term effects. The manner in which outcomes are assessed and the methods employed to make such assessments have changed over time. This review will address these issues as they are related to therapies for type 2 diabetes, including insulin, oral antidiabetes drugs, and incretin-based agents.
引用
收藏
页码:449 / 464
页数:16
相关论文
共 50 条
  • [1] The genetics of type 2 diabetes: what have we learned from GWAS?
    Billings, Liana K.
    Florez, Jose C.
    YEAR IN DIABETES AND OBESITY, 2010, 1212 : 59 - 77
  • [2] Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
    Hanssen, Nordin M. J.
    Jandeleit-Dahm, Karin A. M.
    DIABETES & VASCULAR DISEASE RESEARCH, 2019, 16 (04) : 303 - 309
  • [3] Evolving Treatment Strategies for the Management of Type 2 Diabetes
    Cefalu, William T.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2012, 343 (01) : 21 - 26
  • [4] What we know about counterregulation in Type 2 diabetes
    Heller, SR
    DIABETES NUTRITION & METABOLISM, 2002, 15 (05) : 372 - 375
  • [5] Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?
    Kumar, Ashwini
    Bharti, Sudhanshu Kumar
    Kumar, Awanish
    PHARMACOLOGICAL REPORTS, 2017, 69 (05) : 959 - 970
  • [6] LIXISENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES
    Petersen, A. B.
    Knop, F. K.
    Christensen, M.
    DRUGS OF TODAY, 2013, 49 (09) : 537 - 553
  • [7] The beta-cell in type 1 diabetes: What have we learned from proteomic studies?
    Crevecoeur, Inne
    Rondas, Dieter
    Mathieu, Chantal
    Overbergh, Lut
    PROTEOMICS CLINICAL APPLICATIONS, 2015, 9 (7-8) : 755 - 766
  • [8] Prevention of type 2 diabetes: what challenges do we have to address?
    Schwarz, P. E. H.
    Schwarz, J.
    Bornstein, S. R.
    Schulze, J.
    JOURNAL OF PUBLIC HEALTH-HEIDELBERG, 2005, 13 (06): : 303 - 308
  • [9] What Have We Learned About Acute Pancreatitis in Children?
    Bai, Harrison X.
    Lowe, Mark E.
    Husain, Sohail Z.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2011, 52 (03) : 262 - 270
  • [10] What Have Metabolomics Approaches Taught Us About Type 2 Diabetes?
    Gonzalez-Franquesa, Alba
    Burkart, Alison M.
    Isganaitis, Elvira
    Patti, Mary-Elizabeth
    CURRENT DIABETES REPORTS, 2016, 16 (08)